Migraine is a complex debilitating neurological disorder which is often characterized by recurrent severe headaches in one side of the head. It is generally preceded by sensory warning signs and other symptoms such as sensitivity to light and noise, nausea, vomiting, dizziness, etc. It is one of the most common neurological disorders affecting more than 303 million people in the US alone. Even though the disease leads to huge economic burden, yet migraine remains under-recognized and under-treated. Depending upon the frequency and severity of headaches, there are various treatment options ranging from conventional medicines to supplements.Conventional medicine for migraine treatment can be broadly divided into three categories – Abortive, Preventive and Complementary. Some of the common migraine drug classes include Triptan, Calcitonin Gene-Related Peptide (CGRP), Tezampanel, Acetylcholine Inhibitors/ Neurotoxins, and Ergots Alkaloids. Migraine treatment paradigm is dominated by Triptan drug classes.Global migraine therapeutics market has been relatively stagnant over the past several years. Growth of the market is attributed to the prevalence of migraine and rising female population, as migraine is said to be one of the most common disorders affecting women. Moreover, other growth contributors to the market are patent expiration of leading drugs and stressed lifestyle. However, certain factors that are restraining growth of the market include poor efficacy of drugs, regulatory hurdles, the low diagnosis rate of migraine and preference for alternative therapies.The report “Global Migraine Therapeutics Market [By Drug Classes – Triptan, CGRP, Acetylcholine Inhibitors/Neurotoxins, Others; By Region – North America (The US), Europe (The UK, Germany, France, Italy & Spain) and Asia Pacific (Japan) – Outlook 2025]” provides information on the current scenario, detailed market outlook of the global migraine therapeutics market with detailed analysis of major drug classes such as Triptan, CGRP, Acetylcholine Inhibitors/ Neurotoxins and other drug classes. The market is further analyzed with a detailed market outlook for global as well as regional markets such as North America, Europe, and the Asia Pacific. The analysis is provided for G7 nations. Future forecasts of Migraine treatment market overall and across various sub-segments has been provided till 2025, for all the geographies and all the drug classes. Furthermore, major industry players have been prudently analyzed in the competitive landscape section of the report in order to provide key comparative insights.Major industry players operating in the global migraine therapeutics market include Eli Lilly & Company, Teva Pharmaceutical Industries, Alder Biopharmaceuticals, Amgen Inc., AbbVie Inc., Pfizer Inc., among others. These players are profiled herein based on attributes such as business overview, product segments, and financial analysis. It also compiles the performance comparison of the aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global as well as regional migraine market.Key Factors Impacting Market GrowthPrevalence of migraineStressful Life
https://quincemarketinsights.com/industry-analysis/migraine-therapeutics-market/57961